<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590912</url>
  </required_header>
  <id_info>
    <org_study_id>143</org_study_id>
    <nct_id>NCT03590912</nct_id>
  </id_info>
  <brief_title>Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion</brief_title>
  <official_title>Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumbini Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumbini Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We intend to study the cost of treatment, efficacy and adverse effects for Otitis media with
      effusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment groups would be:

        1. Cefpodoxime + oxymetaxoline drops + levocetirizine

        2. Fluticasone intranasal spray

        3. Short term oral steroids

        4. Wait and watch
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">March 18, 2020</completion_date>
  <primary_completion_date type="Actual">February 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non B type tympanogram</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost of treatment</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Otitis Media With Effusion</condition>
  <arm_group>
    <arm_group_label>Wait and watch (Group D)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait and watch for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone spray (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antibiotic + histaminic + oxymetazoline drops (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral steroid (Group C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone 50 Mcg/Inh Nasal Spray</intervention_name>
    <description>One spray in each nostril once daily for one month</description>
    <arm_group_label>Mometasone spray (Group B)</arm_group_label>
    <other_name>Metaspray nasal spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)</intervention_name>
    <description>Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks</description>
    <arm_group_label>antibiotic + histaminic + oxymetazoline drops (Group A)</arm_group_label>
    <other_name>Syp Cefpodoxime, Syrup levocetirizine 2.5mg/ml; Nasivion drop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid Drug (prednisolone)</intervention_name>
    <description>This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.</description>
    <arm_group_label>Oral steroid (Group C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of mild ear ache or decreased hearing for three or more months, plus

          -  intact and immobile tympanic membrane by pneumatic otoscopy

          -  Type B tympanogram

        Exclusion Criteria:

          -  any external ear condition that hampers visualization of tympanic membrane

          -  lost to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lumbini Medical College</name>
      <address>
        <city>Tansen</city>
        <state>Palpa</state>
        <zip>32500</zip>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
    <mesh_term>Otitis Media with Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefpodoxime</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Nasal Decongestants</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>As soon as the article is published online. Life-long</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

